Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.
Kang YK, George S, Jones RL, Rutkowski P, Shen L, Mir O, Patel S, Zhou Y, von Mehren M, Hohenberger P, Villalobos V, Brahmi M, Tap WD, Trent J, Pantaleo MA, Schöffski P, He K, Hew P, Newberry K, Roche M, Heinrich MC, Bauer S. Kang YK, et al. Among authors: brahmi m. J Clin Oncol. 2021 Oct 1;39(28):3128-3139. doi: 10.1200/JCO.21.00217. Epub 2021 Aug 3. J Clin Oncol. 2021. PMID: 34343033 Free PMC article. Clinical Trial.
Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma.
Dantas-Barbosa C, Lesluyes T, Loarer FL, Chibon F, Treilleux I, Coindre JM, Meeus P, Brahmi M, Bally O, Ray-Coquard I, Sunyach MP, Cesne AL, Mir O, Bonvalot S, Toulmonde M, Italiano A, Saintigny P, Jean-Denis M, Ducimetiere F, Ranchere D, El Sayadi H, Alberti L, Blay JY. Dantas-Barbosa C, et al. Among authors: brahmi m. Br J Cancer. 2017 Dec 5;117(12):1787-1797. doi: 10.1038/bjc.2017.354. Epub 2017 Oct 12. Br J Cancer. 2017. PMID: 29024938 Free PMC article.
Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series.
Frezza AM, Jones RL, Lo Vullo S, Asano N, Lucibello F, Ben-Ami E, Ratan R, Teterycz P, Boye K, Brahmi M, Palmerini E, Fedenko A, Vincenzi B, Brunello A, Desar IME, Benjamin RS, Blay JY, Broto JM, Casali PG, Gelderblom H, Grignani G, Gronchi A, Hall KS, Mir O, Rutkowski P, Wagner AJ, Anurova O, Collini P, Dei Tos AP, Flucke U, Hornick JL, Lobmaier I, Philippe T, Picci P, Ranchere D, Renne SL, Sbaraglia M, Thway K, Wagrodzki M, Wang WL, Yoshida A, Mariani L, Kawai A, Stacchiotti S. Frezza AM, et al. Among authors: brahmi m. JAMA Oncol. 2018 Sep 1;4(9):e180219. doi: 10.1001/jamaoncol.2018.0219. Epub 2018 Sep 13. JAMA Oncol. 2018. PMID: 29800950 Free PMC article.
Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study.
Fucà G, Hindi N, Ray-Coquard I, Colia V, Dei Tos AP, Martin-Broto J, Brahmi M, Collini P, Lorusso D, Raspagliesi F, Pantaleo MA, Vincenzi B, Fumagalli E, Gronchi A, Casali PG, Sanfilippo R. Fucà G, et al. Among authors: brahmi m. Oncologist. 2019 Jul;24(7):e536-e541. doi: 10.1634/theoncologist.2018-0338. Epub 2018 Dec 5. Oncologist. 2019. PMID: 30518617 Free PMC article.
Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas).
Sanfilippo R, Jones RL, Blay JY, Le Cesne A, Provenzano S, Antoniou G, Mir O, Fucà G, Fumagalli E, Bertulli R, Stacchiotti S, Brahmi M, Grosso F, Dufresne A, Hindi N, Sbaraglia M, Gronchi A, Collini P, Dei Tos AP, Casali PG. Sanfilippo R, et al. Among authors: brahmi m. Clin Cancer Res. 2019 Sep 1;25(17):5295-5300. doi: 10.1158/1078-0432.CCR-19-0288. Epub 2019 Jun 19. Clin Cancer Res. 2019. PMID: 31217199 Free article.
The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis.
Baldi GG, Brahmi M, Lo Vullo S, Cojocaru E, Mir O, Casanova M, Vincenzi B, De Pas TM, Grignani G, Pantaleo MA, Blay JY, Jones RL, Le Cesne A, Frezza AM, Gronchi A, Collini P, Dei Tos AP, Morosi C, Mariani L, Casali PG, Stacchiotti S. Baldi GG, et al. Among authors: brahmi m. Oncologist. 2020 Nov;25(11):e1777-e1784. doi: 10.1634/theoncologist.2020-0352. Epub 2020 Jul 12. Oncologist. 2020. PMID: 32584482 Free PMC article.
Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG "ANITA".
Schöffski P, Toulmonde M, Estival A, Marquina G, Dudzisz-Śledź M, Brahmi M, Steeghs N, Karavasilis V, de Haan J, Wozniak A, Cousin S, Domènech M, Bovée JVMG, Charon-Barra C, Marreaud S, Litière S, De Meulemeester L, Olungu C, Gelderblom H. Schöffski P, et al. Among authors: brahmi m. Eur J Cancer. 2021 Jul;152:26-40. doi: 10.1016/j.ejca.2021.04.015. Epub 2021 May 29. Eur J Cancer. 2021. PMID: 34062484 Free article. Clinical Trial.
TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials.
Nassif EF, Auclin E, Bahleda R, Honoré C, Mir O, Dumont S, Mery B, Hodroj K, Brahmi M, Trédan O, Ray-Coquard I, Blay JY, Massard C, Le Cesne A, Dufresne A. Nassif EF, et al. Among authors: brahmi m. Cancers (Basel). 2021 Jul 5;13(13):3362. doi: 10.3390/cancers13133362. Cancers (Basel). 2021. PMID: 34282771 Free PMC article.
90 results